giotrif
Additional data for Boehringer’s Giotrif combo shows strong overall survival benefit in lung cancer sub-population
August 5, 2019Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, giotrif, lung cancer, pharma
German firm Boehringer Ingelheim has released new interim data from a real-world evidence study investigating the efficacy of Giotrif/Gilotrif (afatinib) …
Boehringer Ingelheim’s Giotrif significantly lowers lung cancer progression in Phase II trials
April 13, 2016Research and Development AstraZeneca, Boehringer Ingelheim, Iressa, giotrif, lung cancer
German drugmaker Boehringer Ingelheim on Wednesday said a mid-stage study has shown its cancer drug Giotrif (afatinib) reduced the risk …
Boehringer Ingelheim’s Giotrif gets Europan regulatory backing in another lung cancer indication
April 7, 2016Business Services, Research and Development, Sales and Marketing Boehringer Ingelheim, European Commission, giotrif, lung cancer
German drugmaker Boehringer Ingelheim on Thursday said European regulators have granted marketing rights for its non-small cell lung cancer (NSCLC) …
Boehringer and Sanofi admit to code breaches
February 13, 2015Medical Communications, Sales and Marketing ABPI, Boehringer, PMCPA, Sanofi, afatinib, giotrif
Sanofi and Boehringer Ingelheim have both admitted to breaching the ABPI Code of Practice, with Sanofi set to be publicly …
Boehringer blood cancer drug scores in Phase II
July 9, 2014Research and Development, Sales and Marketing Boehringer, blood, giotrif, leukaemia, volasertib
Less than a year after securing its first cancer drug on the market with Giotrif, Boehringer has taken another decisive …
Boehringer lung cancer drug shows survival benefit
June 3, 2014Sales and Marketing ASCO, Boehringer, NSCLC, afatinib, giotrif, lung cancer
A new analysis of two late-stage trials shows that Boehringer drug Giotrif extends overall survival in a large proportion of …
Giotrif increases lung cancer survival
May 16, 2014Research and Development, Sales and Marketing Boehringer, Iressa, Roche, Tarceva, afatinib, giotrif, lung cancer
Boehringer Ingelheim is trumpeting overall survival results from a new analysis of two late-stage studies involving Giotrif in lung cancer …
Boehringer’s first cancer drug gains NICE yes
March 17, 2014Sales and Marketing Boehringer, Cancer, NICE, NSCLC, afatinib, giotrif
NICE is recommending that Boehringer Ingelheim’s first oncology treatment Giotrif be funded by the NHS. The new final draft guidance …
